Please assess the completion status of the following clinical trial:

Trial Title: Kisspeptin in the Evaluation of Delayed Puberty

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Adolescent Boys~* ages 13.5-17 years~* testicular volume \<4 mL OR 4-8 ml with no change in the past 6 months by Prader orchidometer~* first morning (before 9AM) LH \<2 mIU/mL and testosterone \<50 ng/dL~Adolescent Girls~* ages 12-17 years~* Tanner stage I OR II breast development with no change in the past 6 months~* first morning (before 9AM) LH \<2 mIU/mL and estradiol \<20 pg/ml~All Subjects:~* bone age less than chronological age~* weight ≥ 28 kg~* body mass index \>10th percentile and \<+3 SDS for bone age~* blood pressure \>5th percentile and \<95th percentile for bone age and height~* white blood cell counts, platelet counts, electrolytes, thyroid stimulating hormone (TSH), free thyroxine (T4) within reference range for age~* erythrocyte sedimentation rate \<2X the upper limit of the reference range for age~* hemoglobin within reference range for girls of the same chronological age~* blood urea nitrogen (BUN), creatinine, prolactin not elevated~* aspartate aminotransferase (AST) and alanine aminotransferase (ALT) no more than 2X the upper limit of the reference range~* Insulin-like growth factor 1 (IGF-1) within reference range for bone age~Exclusion Criteria:~All Subjects:~* history or presence of underlying condition that could cause delayed puberty (chronic illness, weight loss, abnormal cranial magnetic resonance imaging (MRI))~* history of an allergic drug reaction

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Kisspeptin, GnRH (Type: EXPERIMENTAL): Intravenous (IV) administration of kisspeptin 112-121 0.24 nmol/kg and GnRH 75 ng/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).